Lucentis and Urticaria aggravated - a phase IV clinical study of FDA data

Summary:

Urticaria aggravated is reported as a side effect among people who take Lucentis (ranibizumab), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Visudyne, and have Age-related macular degeneration.

The phase IV clinical study analyzes which people have Urticaria aggravated when taking Lucentis. It is created by eHealthMe based on reports of 25,577 people who have side effects when taking Lucentis from the FDA, and is updated regularly.

What is Lucentis?

Lucentis has active ingredients of ranibizumab. It is often used in macular degeneration. eHealthMe is studying from 25,647 Lucentis users. Check the latest studies of Lucentis.

What is Urticaria aggravated?

Urticaria aggravated (rash of round, red welts on the skin that itch intensely) is found to be associated with 2,059 drugs and 720 conditions by eHealthMe. Check the latest studies of Urticaria aggravated.

On Jul, 16, 2026

25,577 people reported to have side effects when taking Lucentis.
Among them, 72 people (0.28%) have Urticaria aggravated.

Could Lucentis cause Urticaria aggravated?

Among these 72 people:

How long have people been on Lucentis when they have Urticaria aggravated? *

What is the gender of people who have Urticaria aggravated when taking Lucentis? *

female: 62.86 %
male: 37.14 %

What is the age of people who have Urticaria aggravated when taking Lucentis? *

What are other drugs people take besides Lucentis? *

What are other side effects people have besides Urticaria aggravated? *

Rashes (redness): 14 people, 19.44%
Dyspnea (difficult or laboured breathing): 13 people, 18.06%
Itching: 10 people, 13.89%
Age-Related Macular Degeneration: 9 people, 12.50%
Angioedema (rapid swelling of the dermis): 9 people, 12.50%
Diarrhea: 8 people, 11.11%
Visual Acuity Reduced (reduced clearness of vision): 8 people, 11.11%
Contrast Media Allergy (reaction associated with the use of intravenous contrast material during radiology): 8 people, 11.11%
Cataract (clouding of the lens inside the eye): 8 people, 11.11%
Disease Progression: 7 people, 9.72%

What are the existing conditions these people have? *

Age-Related Macular Degeneration: 14 people, 19.44%
Polypoidal Choroidal Vasculopathy (polyp-like sub-retinal pigment epithelium vascular abnormalities predominantly found in the macula and peripapillary region): 7 people, 9.72%
Asthma: 6 people, 8.33%
Retinal Vessel Occlusion (a blockage in one of the small arteries): 5 people, 6.94%
Diabetes: 5 people, 6.94%
Vaginal Infection: 3 people, 4.17%
Retinopathy (acute damage to the retina of the eye): 3 people, 4.17%
Diabetic Retinal Oedema (excessive build-up of fluid in the retina due to diabetes): 3 people, 4.17%
Macular Oedema (fluid and protein deposits collect on or under the macula of the eye (a yellow central area of the retina) and causes it to thicken): 3 people, 4.17%
High Blood Cholesterol: 2 people, 2.78%

* Approximation only. Some reports may have incomplete information.

Do you take Lucentis and have Urticaria aggravated?

- Check whether Urticaria aggravated is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Lucentis:

Lucentis (25,647 reports)

Browse all side effects of Lucentis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Urticaria aggravated:

Urticaria aggravated (2,059 drugs)

Browse all the conditions that are associated with Urticaria aggravated:

Urticaria aggravated (720 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on ranibizumab (the active ingredients of Lucentis) and Lucentis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.